COO Cooper Companies Inc.

CooperGenomics Receives ISO 15189 Accreditation in United Kingdom Laboratories for Noninvasive Prenatal Testing

LONDON--(BUSINESS WIRE)--

CooperGenomics, a CooperSurgical company which includes Reprogenetics, Recombine, and Genesis Genetics, is pleased to announce the receipt of ISO 15189 accreditation for both its London and Nottingham-based laboratories. Issued by the United Kingdom Accreditation Services (UKAS), this certification validates the quality and accuracy of the genetic testing services provided by the laboratories.

The accreditation includes all noninvasive prenatal testing (NIPT), preimplantation genetic diagnosis (PGD), and preimplantation genetic screening (PGS) services provided in the CooperGenomics London and Nottingham facilities. CooperGenomics is the first laboratory in the United Kingdom to receive such accreditation for NIPT and PGS services.

“We are honoured to have received this accreditation from UKAS,” said Tony Gordon, PhD, Vice President of Business Development at CooperGenomics in the UK. “As a leader in the field of reproductive genetic testing, we pride ourselves on the quality of our services, to which this certification is a testament.”

About CooperSurgical

For more than 25 years, CooperSurgical has been a leader in manufacturing and marketing a wide range of trusted and innovative brands that have assisted clinicians in advancing the standard of health care for women worldwide. Through an aggressive growth and diversification strategy, CooperSurgical has evolved its portfolio to include key products and services for women’s health, fertility and genetic testing. Our global in vitro fertilization (IVF) segment, ORIGIO, and our groundbreaking offering from the pioneers of genetic testing, Recombine/Reprogenetics/Genesis Genetics, complement our dynamic women’s health care offering.

CooperSurgical, Inc. is a wholly owned subsidiary of The Cooper Companies (NYSE: COO) and is headquartered in Trumbull, CT. Through the delivery of insightful technologies and products to health care providers, we envision a world with healthier babies, individuals, and families. More information can be found at www.coopersurgical.com.

EN
08/03/2017

Underlying

COOCooper Companies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cooper Companies Inc.

 PRESS RELEASE
Free
COO Cooper Companie...

CooperCompanies to Present at the J.P. Morgan Healthcare Conference

CooperCompanies to Present at the J.P. Morgan Healthcare Conference SAN RAMON, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will participate at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Al White, President and CEO, will represent the Company in a session scheduled to begin at 5:15pm ET. A live and archived webcast of the event, where applicable, will be available on the CooperCompanies’ website at . About CooperCompaniesCooperCompanies (Nasdaq: COO) is a leading global medical de...

December 29, 2025 1 EN
Free Trial
COO Cooper Companie...

Cooper Companies Inc: 1 director

A director at Cooper Companies Inc bought 1,784 shares at 84.060USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

COO COOPER COMPANIES INC.
12/23/25 December 23, 2025 1 EN
 PRESS RELEASE
Free
COO Cooper Companie...

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Dire...

CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors Enters into Cooperation Agreement with Browning West SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that the Company’s Board of Directors (the “Board”) has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the “Cooperation Agreement”) with Browning West, LP. (“Browning West”). Mr....

December 23, 2025 1 EN
 PRESS RELEASE
Free
COO Cooper Companie...

CooperCompanies Announces New Chair of the Board and Strategic Review

CooperCompanies Announces New Chair of the Board and Strategic Review SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today that its Board of Directors has appointed Colleen Jay to succeed current Chair Robert Weiss, effective January 2, 2026. Mr. Weiss will remain on the Board and stand for reelection for the upcoming year, marking his final term. The Company also announced a formal strategic review aimed at identifying opportunities to enhance long-term shareholder value. “Bob’s vision, industry knowledge, ...

December 4, 2025 1 EN
 PRESS RELEASE
Free
COO Cooper Companie...

CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

CooperCompanies Announces Fourth Quarter and Full Year 2025 Results SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically.Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025 GAAP diluted EPS of $1.87, down 4%.Fourth quarter 2025 non-GA...

December 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch